Discovery of dinaciclib (SCH 727965): A potent and selective inhibitor of cyclin-dependent kinases
Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability paramete
Paruch, Kamil,Dwyer, Michael P.,Alvarez, Carmen,Brown, Courtney,Chan, Tin-Yau,Doll, Ronald J.,Keertikar, Kerry,Knutson, Chad,McKittrick, Brian,Rivera, Jocelyn,Rossman, Randall,Tucker, Greg,Fischmann, Thierry,Hruza, Alan,Madison, Vincent,Nomeir, Amin A.,Wang, Yaolin,Kirschmeier, Paul,Lees, Emma,Parry, David,Sgambellone, Nicole,Seghezzi, Wolfgang,Schultz, Lesley,Shanahan, Frances,Wiswell, Derek,Xu, Xiaoying,Zhou, Quiao,James, Ray A.,Paradkar, Vidyadhar M.,Park, Haengsoon,Rokosz, Laura R.,Stauffer, Tara M.,Guzi, Timothy J.
scheme or table
p. 204 - 208
(2010/12/20)
Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates
This application discloses a novel process to synthesize (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives, and intermediates useful in the synthesis thereof. The subject (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives are useful as cyclin-dependent kinase inhibitor compounds (CDK inhibitors) in pharmaceutical preparations.
-
Page/Page column 14
(2008/06/13)
More Articles about upstream products of 779353-65-0